KOSPIBiotech & Pharma003520

Yungjin Pharm

₩741▼ 2.76%2026-11-18 close
Market Cap
₩135.5B
Turnover
₩200M
Volume
330K
Shares out.
180M
PER
—
PBR
1.7×
EPS
-₩43
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Four Straight Loss Quarters; Export Decline in Focus

Yungjin Pharm kept full-year 2025 operating profit positive at KRW 3.42 billion, but it has booked operating losses in each of the four quarters from Q4 2025 through Q3 2026 while overseas sales have fallen.

  1. 1

    Full-year 2025 operating profit was KRW 3.42 billion, down 60.8% year on year, with an operating margin of 1.3%.

  2. 2

    The company has posted operating losses for four straight quarters from Q4 2025 to Q3 2026, and attributable net losses over those four quarters totaled KRW 7.87 billion.

  3. 3

    Overseas sales fell 45.7% to KRW 6.8 billion in the first half of 2026, while a KRW 64.2 billion supply contract for Cefcapene granules in China was recorded as confirmed in the half-year report.

  4. 4

    The debt ratio rose from 126.0% in 2022 to 186.9% in 2025; at year-end 2025 total liabilities were KRW 170.9 billion against total equity of KRW 91.5 billion.

  5. 5

    Press reports put potential KL1333 milestones in the several-hundred-billion-won range, with timing tied to clinical progress.

02

Business structure

Yungjin Pharm runs a prescription drug business that combines cephalosporin antibiotics, the enteral nutrition product Hamonilan, sales of multinational pharmaceutical partners' products, and contract manufacturing.

In the first half of 2026, per the half-year report, merchandise sales were KRW 63.4 billion, product sales KRW 44.8 billion, processing fees KRW 15.9 billion and raw materials KRW 900 million, making merchandise the largest category.

Among product sales, Hamonilan was largest at KRW 19.6 billion, followed by the diabetes drug Diamicron at KRW 4.1 billion and the antibiotic kit Trisonkit at KRW 4 billion. Overseas sales were KRW 6.8 billion in the first half of 2026, down 45.7%, and Japan sales fell 45.0% to KRW 6 billion.

Overseas sales had exceeded 28% of revenue before COVID-19 but dropped to 14.72% in 2021. Cefcapene granules are made in Korea and marketed in China by a local partner; a previously reported contract carried a total value of about KRW 99.5 billion over ten years from approval.

R&D spending in the first half of 2026 was KRW 6.8 billion, or 5.4% of sales. The pipeline centers on KL1333 for mitochondrial disease, alongside YPL-001 for asthma and COPD and YRA-1909 for rheumatoid arthritis. The company is recorded as an affiliate of KT&G in its Q3 2026 preliminary disclosure.

Within the sector, Yungjin Pharm earns more of its profit from sales and contract business than from licensing new drugs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩60.9B₩3,644,2570.0%
2025Q4₩66.8B-₩1.1B−1.6%
2026Q1₩63.8B-₩1.8B−2.8%
2026Q2₩61.6B-₩1.5B−2.4%
2026Q3₩62.7B-₩2.3B−3.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩218.4B-₩7.4B-₩22B−3.4%−24.4%126.0%
2023₩234.9B₩3.1B-₩3.9B1.3%−4.3%152.8%
2024₩252B₩8.7B₩1.2B3.5%1.4%160.9%
2025₩254.3B₩3.4B-₩200M1.3%−0.2%186.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue rose from KRW 218.4 billion in 2022 to KRW 234.9 billion in 2023 (up 7.6% year on year), KRW 252 billion in 2024 (up 7.3%) and KRW 254.3 billion in 2025 (up 0.9%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating results moved from an operating loss of KRW 7.36 billion in 2022 to an operating profit of KRW 3.12 billion in 2023, a swing to profit; operating profit then rose to KRW 8.72 billion in 2024 (up 179.8%) before falling to KRW 3.42 billion in 2025 (down 60.8%).

The operating margin was 1.3% in 2023, 3.5% in 2024 and 1.3% in 2025, so margins stayed thin even as sales grew.

Attributable net income turned to a profit of KRW 1.23 billion in 2024 but swung back to an attributable net loss of KRW 228 million in 2025; net income including non-controlling interests moved in the same direction.

Press coverage has pointed to the high share of merchandise sales and the cost of sales ratio as a drag on margins; in Q1 2025 merchandise sales were KRW 26.2 billion, or 40% of revenue, with a cost of sales ratio of 69%.

Quarterly, operating profit of KRW 3.64 million in Q3 2025 turned into an operating loss of KRW 1.09 billion in Q4 2025, followed by losses of KRW 1.75 billion in Q1 2026, KRW 1.5 billion in Q2 2026 and KRW 2.29 billion in Q3 2026.

Revenue in Q3 2026 was KRW 62.7 billion, up 3.1% year on year, but the quarter moved to an operating loss. The preliminary Q3 2026 disclosure dated November 4, 2026 showed a cumulative operating loss of KRW 5.547 billion and a cumulative net loss of KRW 7.491 billion for January to September, unaudited.

Operating cash flow stayed positive at KRW 21.7 billion in 2024 and KRW 11.7 billion in 2025. The debt ratio rose from 126.0% in 2022 to 186.9% in 2025, with total liabilities of KRW 170.9 billion and total equity of KRW 91.5 billion at year-end 2025.

05

Industry analysis

Yungjin Pharm's export trajectory moved sharply around COVID-19. Overseas sales had exceeded 28% of revenue before the pandemic but fell to 14.72% in 2021 as cephalosporin antibiotic exports declined.

Press reports said export volumes recovered in 2023 as conditions improved, and that domestic contract business growth lifted results.

Overseas sales, however, fell 45.7% to KRW 6.8 billion in the first half of 2026, and Japan sales fell 45.0%, so whether the export recovery continues will show in upcoming half-year results.

On the earnings structure, analysts have noted that merchandise sales, which depend on multinational partners' distribution rights, carry thin margins. In Q1 2025 merchandise sales were KRW 26.2 billion, or 40% of revenue, with a cost of sales ratio of 69%.

Domestically, Hamonilan remains the core product, with first-half 2026 sales of KRW 19.6 billion. Antibiotic capacity has been expanded through the Namyang plant upgrade.

Compared with other listed companies in the biopharma sector, Yungjin Pharm relies more visibly on sales and contract revenue than on licensing income from new drugs. Unless the cost ratio and merchandise mix change, operating margins are likely to stay in a narrow band.

06

Outlook

The Namyang plant upgrade for injectable antibiotics was decided in 2022. A 2024 report said production capacity would expand from 8 million vials to 20 million vials and that operations were expected from the second half of 2025.

The investment was reported at KRW 21.5 billion, while another report put the construction cost at KRW 22.6 billion, so the figures differ. Whether the expansion has added revenue will be checked in the 2026 annual report.

Cefcapene granules received a filing for marketing approval in China, with approval expected roughly two years after filing, and the contract covers about KRW 100 billion in finished product supply over ten years after approval.

How the KRW 64.2 billion supply contract recorded in the 2026 half-year report connects to that agreement is a point to verify against the detailed disclosures.

In the pipeline, KL1333 passed the safety and futility assessment at its Phase 2 interim analysis and continues in a 180-patient trial, and it has received FDA Fast Track designation. If clinical development and commercialization succeed, several hundred billion won in milestones are expected, with royalties on top.

The company holds the rights in Korea and Japan. A generic version of Opdivo-type capsule product, Ofev-equivalent generic, was reported as having its marketing application submitted to the Ministry of Food and Drug Safety.

In upcoming periodic reports, the timing of how these pipeline items enter revenue and operating margin is the key point to track.

07

Valuation

PER
—
PBR
1.7×
ROE
-9.1%
EPS
-₩43
BPS
₩455
Dividend per share
₩0

Yungjin Pharm's price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters, so earnings-based multiples are hard to compare with other companies. The price-to-book ratio sits above 1x, meaning the market price carries a premium to book equity.

Total equity and attributable equity were both KRW 91.5 billion at year-end 2025, which gives an asset-based starting point for comparison. The debt ratio rising from 126.0% in 2022 to 186.9% in 2025 also reflects a heavier liability load relative to assets.

The dividend yield is effectively nil, which places the company below the sector average on shareholder payouts. On an annual basis, the company swung from profit in 2024 to a net loss in 2025, and the quarterly losses since Q4 2025 mean earnings-based indicators are likely to stay uncalculated for now.

Comparing a historical valuation band with current levels has limited meaning after the swing to losses. How valuation reads will change with the operating income trend and capital structure in upcoming periodic reports.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

China Cefcapene supply contract

The 2026 half-year report recorded a KRW 64.2 billion supply contract for Cefcapene granules in China as confirmed. A previously reported contract carried a total value of about KRW 99.5 billion over ten years from approval.

The agreement covers roughly KRW 100 billion in finished product supply over that period, which gives a reference point for export revenue visibility. Approval was expected to take around two years after filing.

KL1333 pipeline progress

Press reports from 2024 said KL1333, a mitochondrial disease candidate, passed safety and futility review at its Phase 2 interim analysis and can continue in a 180-patient trial. It also holds FDA Fast Track designation.

Clinical and commercial success could bring milestones in the several-hundred-billion-won range, with royalties separate. The company retains rights in Korea and Japan, which is cited as an added source of potential income.

Annual profit trend sustained

After an operating loss of KRW 7.36 billion in 2022, operating profit turned positive at KRW 3.12 billion in 2023 and reached KRW 8.72 billion in 2024. Operating cash flow was KRW 11.7 billion in 2025. The annual profit pattern stands in contrast with the concentrated quarterly losses now visible. Operating profit still fell to KRW 3.42 billion in 2025 from 2024.

09

Bear factors

Continued quarterly operating losses

Operating losses have run for four straight quarters from Q4 2025 through Q3 2026, and attributable net losses have run for five straight quarters from Q3 2025. The Q3 2026 operating loss widened to KRW 2.29 billion.

Per the preliminary disclosure dated November 4, 2026, the cumulative operating loss for January to September was KRW 5.547 billion.

Overseas sales contraction

Overseas sales fell 45.7% to KRW 6.8 billion in the first half of 2026, with Japan down 45.0% to KRW 6 billion and other regions down 50.2%. The overseas share had dropped to 14.72% in 2021. The first-half report shows domestic sales grew 3.9%, which did not offset the export decline.

Thin margins from merchandise sales

Merchandise sales, which depend on multinational partners' rights, carry low margins according to analysts. Merchandise was the largest first-half 2026 category at KRW 63.4 billion. With a Q1 2025 cost of sales ratio of 69%, room for margin improvement looks limited. The 2025 operating margin was 1.3%.

10

Risk factors

Balance sheet

Total liabilities at year-end 2025 were KRW 170.9 billion against total equity of KRW 91.5 billion, a debt ratio of 186.9%. The ratio rose from 126.0% in 2022 through 152.8% in 2023 and 160.9% in 2024. A May 2025 press report said partial capital impairment persisted. Continued operating losses could weigh on equity capacity.

Overseas and export markets

Overseas sales fell 45.7% in the first half of 2026 and Japan sales fell 45.0%. Revenue timing for Cefcapene supply to China could shift with approval. If overseas sales do not recover, the path back to quarterly operating profit narrows. Whether exports recover will show in the overseas sales line of upcoming half-year reports.

Clinical and approval timing

Success and timing for KL1333 clinical development and commercialization remain uncertain, and milestone amounts are reported only as ranges. Chinese approval timing and the Namyang plant start-up depend on company schedules.

R&D spending was KRW 6.8 billion in the first half of 2026, or 5.4% of sales, keeping cost pressure in place. Delays would push back the timing of a return to quarterly profit.

11

What to watch next

  1. Around January 2027 (date not confirmed)

    Check whether the Q4 2026 preliminary results extend the run of operating losses to five quarters and how the loss size changes. Preliminary figures remain subject to external audit.

  2. Late March 2027 (around the statutory deadline for the annual report)

    The 2026 annual report will show the full-year operating margin, debt ratio, merchandise and product sales mix, and whether the Namyang plant expansion has started contributing revenue.

  3. Mid-August 2027 (around the half-year report deadline)

    Check whether first-half 2027 overseas sales break from the 45.7% decline of first-half 2026 and whether Cefcapene supply revenue begins to show.

  4. Timing not fixed (per company disclosures)

    Watch the NMPA decision on Cefcapene granules and the follow-up results of the KL1333 trial. Both events could change the timing of milestone and export revenue recognition.

12

Overall view

Yungjin Pharm kept full-year 2025 operating profit positive at KRW 3.42 billion, but operating losses have run for four straight quarters since Q4 2025 and overseas sales fell 45.7% in the first half of 2026.

Factors on the positive side include the KRW 64.2 billion Cefcapene supply contract recorded in the half-year report, potential KL1333 milestones tied to clinical progress, and the annual profit pattern since 2023.

Factors on the negative side include persistent quarterly losses, thin margins from merchandise sales, and the financial burden of a 186.9% debt ratio. Operating cash flow stayed positive at KRW 11.7 billion in 2025, which provides a cushion, but its durability depends on an improvement in the income statement.

Valuation sits with the price-to-book ratio above 1x while earnings-based multiples cannot be calculated. Items to track are the Q4 2026 preliminary results, the operating margin and debt ratio in the 2026 annual report, the Namyang plant status and the Chinese approval process. This report is for information only and does not offer an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. kormedi.com
  2. m.dailypharm.com
  3. medipana.com
  4. medicaltimes.com
  5. msn.com
  6. newsthevoice.com
  7. businessreport.kr
  8. medisobizanews.com
  9. medipana.com
  10. news.mtn.co.kr
  11. news.nate.com
  12. pflow.keywordegg.com
  13. biobookmedia.com
  14. m.news.nate.com
  15. etoday.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis